Two Sigma Investments LP Sells 77,124 Shares of Repligen Co. (NASDAQ:RGEN)

Two Sigma Investments LP cut its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 17.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 359,039 shares of the biotechnology company's stock after selling 77,124 shares during the quarter. Two Sigma Investments LP owned 0.64% of Repligen worth $51,680,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. UMB Bank n.a. raised its stake in shares of Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 110 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in shares of Repligen in the fourth quarter worth approximately $216,000. Van ECK Associates Corp raised its stake in shares of Repligen by 7.8% in the fourth quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company's stock worth $6,078,000 after purchasing an additional 3,066 shares during the last quarter. Stephens Investment Management Group LLC raised its stake in shares of Repligen by 7.4% in the fourth quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company's stock worth $77,267,000 after purchasing an additional 37,057 shares during the last quarter. Finally, LPL Financial LLC raised its stake in shares of Repligen by 47.6% in the fourth quarter. LPL Financial LLC now owns 32,237 shares of the biotechnology company's stock worth $4,873,000 after purchasing an additional 10,395 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Repligen

In other Repligen news, Director Margaret Pax acquired 250 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This represents a 31.53% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.20% of the stock is owned by corporate insiders.

Repligen Stock Performance

NASDAQ RGEN traded down $2.30 on Friday, hitting $118.15. 615,767 shares of the stock traded hands, compared to its average volume of 740,875. The business's fifty day moving average is $130.28 and its two-hundred day moving average is $144.48. Repligen Co. has a 12 month low of $102.97 and a 12 month high of $182.52. The firm has a market capitalization of $6.64 billion, a price-to-earnings ratio of -231.67, a PEG ratio of 4.54 and a beta of 1.21. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. During the same period last year, the company earned $0.28 earnings per share. The business's revenue for the quarter was up 10.4% on a year-over-year basis. As a group, equities analysts anticipate that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Royal Bank of Canada lowered their price objective on Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research note on Wednesday, April 30th. Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective for the company in a research note on Tuesday, April 29th. Canaccord Genuity Group lowered their price objective on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research note on Wednesday, April 16th. Wall Street Zen raised Repligen from a "sell" rating to a "hold" rating in a research report on Thursday, May 8th. Finally, JPMorgan Chase & Co. decreased their price target on Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $173.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.